Forum for Science, Industry and Business

Sponsored by:     3M 
Search our Site:

 

Intensively lowering glucose: Possible benefits must be weighed against risks

30.06.2010
Lead author of Lancet paper from clinical site University Hospitals Case Medical Center

In an analysis from the Action to Control Cardiovascular Risk in Diabetes (ACCORD) trial, one of the largest studies of its kind to determine whether intensive blood glucose (sugar) control worked better than standard blood sugar control among diabetics, results show that the benefits of intensive therapy need to be balanced against the increase in total and cardiovascular disease-related death, increased weight gain, and high risk for severe low blood sugar.

The study is published by the Lancet to coincide with the American Diabetes Association's 70th Scientific Sessions in Orlando. The analysis is written by Dr. Faramarz Ismail-Beigi, a diabetes specialist with University Hospitals Case Medical Center, Case Western Reserve University, and colleagues for the ACCORD trial group.

ACCORD was a randomised trial done with more than 10,000 patients in 77 clinical sites, including University Hospitals Case Medical Center, in North America. People with Type 2 diabetes for an average of 10 years, high blood sugar concentrations and cardiovascular disease were randomly assigned to an intensive lowering of blood sugars or standard therapy.

The study examined patients who underwent intensive glucose-lowering treatment for 3.5 years (increased medication aimed at lowering A1C levels to less than 6 percent) and were then given standard treatments (aimed at achieving A1C levels of 7.0-7.9 percent) for the remaining 1.5 years, compared with standard treatment for the duration of the study. The intensively treated patients did not see a reduced incidence of cardiovascular disease.

In addition, the groups did not differ in overall measures of microvascular health, for example, in the progression rates to kidney failure, major vision loss, or advanced peripheral neuropathy, a common nerve problem in diabetes that usually begins as tingling or numbness in the feet.

However, there were some microvascular improvements noted, such as a reduced incidence of albuminuria (protein in the urine, a marker of kidney disease) in the intensive group, compared to those receiving standard treatment, along with fewer cataract extractions during the study period. Visual acuity (sharpness of vision) and nerve function scores also were better for the intensive group than for the standard-treatment group, suggesting that intensive lowering of blood glucose may also help prevent eye and nerve damage.

"Patients who develop macroalbuminuria are prone to renal failure and cardiovascular events," said Dr. Ismail-Beigi, the lead researcher on this portion of the ACCORD trial. "Less protein in the urine is a very good sign."

Though the visual acuity tests were somewhat subjective, Dr. Ismail-Beigi said, they could indicate that intensive glucose lowering helps to prevent eye damage.

Dr. Ismail-Beigi said that the study indicates the importance of individualized, patient-centered therapy for patients. A decision on the aggressiveness of therapy depends on what stage of the disease patients are in. For those patients who are newly diagnosed with diabetes, intensive, aggressive therapy could delay the onset of some of the complications of diabetes, such as kidney disease and eye problems. For patients who have had diabetes 10 years or longer and have complicating heart factors, intense therapy would not be prudent because of the associated higher risk of cardiovascular death.

The National Heart Lung and Blood Institute, which sponsored this landmark study, prematurely halted the intensive blood-glucose lowering strategy after 3.5 years, in February 2008, due to safety concerns caused by an unexpected higher incidence of death in the intensive glucose lowering treatment group compared with the standard treatment group. Patients in the intensive treatment arm of the study were transitioned into the standard treatment arm for the remainder of the trial's five years, which has now concluded.

Other portions of the ACCORD trial confirmed that neither more intensive lowering of blood pressure nor treatment of blood lipids with a fibrate and a statin drug reduce cardiovascular risk in people with established type 2 diabetes who are at severely high risk for cardiovascular events.

About University Hospitals

University Hospitals serves the needs of patients through an integrated network of hospitals, outpatient centers and primary care physicians. At the core of our health system is University Hospitals Case Medical Center. The primary affiliate of Case Western Reserve University School of Medicine, University Hospitals Case Medical Center is home to some of the most prestigious clinical and research centers of excellence in the nation and the world, including cancer, pediatrics, women's health, orthopedics and spine, radiology and radiation oncology, neurosurgery and neuroscience, cardiology and cardiovascular surgery, organ transplantation and human genetics. Its main campus includes the internationally celebrated UH Rainbow Babies & Children's Hospital, ranked second in the nation for the care of critically ill newborns; UH MacDonald Women's Hospital, Ohio's only hospital for women; and UH Ireland Cancer Center, part of the NCI-designated Case Comprehensive Cancer Center. For more information, go to www.uhhospitals.org

George Stamatis | EurekAlert!
Further information:
http://www.uhhospitals.org

More articles from Health and Medicine:

nachricht Chances to treat childhood dementia
24.07.2017 | Julius-Maximilians-Universität Würzburg

nachricht World first: Massive thrombosis removed during early pregnancy
20.07.2017 | Universitätsspital Bern

All articles from Health and Medicine >>>

The most recent press releases about innovation >>>

Die letzten 5 Focus-News des innovations-reports im Überblick:

Im Focus: 3-D scanning with water

3-D shape acquisition using water displacement as the shape sensor for the reconstruction of complex objects

A global team of computer scientists and engineers have developed an innovative technique that more completely reconstructs challenging 3D objects. An ancient...

Im Focus: Manipulating Electron Spins Without Loss of Information

Physicists have developed a new technique that uses electrical voltages to control the electron spin on a chip. The newly-developed method provides protection from spin decay, meaning that the contained information can be maintained and transmitted over comparatively large distances, as has been demonstrated by a team from the University of Basel’s Department of Physics and the Swiss Nanoscience Institute. The results have been published in Physical Review X.

For several years, researchers have been trying to use the spin of an electron to store and transmit information. The spin of each electron is always coupled...

Im Focus: The proton precisely weighted

What is the mass of a proton? Scientists from Germany and Japan successfully did an important step towards the most exact knowledge of this fundamental constant. By means of precision measurements on a single proton, they could improve the precision by a factor of three and also correct the existing value.

To determine the mass of a single proton still more accurate – a group of physicists led by Klaus Blaum and Sven Sturm of the Max Planck Institute for Nuclear...

Im Focus: On the way to a biological alternative

A bacterial enzyme enables reactions that open up alternatives to key industrial chemical processes

The research team of Prof. Dr. Oliver Einsle at the University of Freiburg's Institute of Biochemistry has long been exploring the functioning of nitrogenase....

Im Focus: The 1 trillion tonne iceberg

Larsen C Ice Shelf rift finally breaks through

A one trillion tonne iceberg - one of the biggest ever recorded -- has calved away from the Larsen C Ice Shelf in Antarctica, after a rift in the ice,...

All Focus news of the innovation-report >>>

Anzeige

Anzeige

Event News

Closing the Sustainability Circle: Protection of Food with Biobased Materials

21.07.2017 | Event News

»We are bringing Additive Manufacturing to SMEs«

19.07.2017 | Event News

The technology with a feel for feelings

12.07.2017 | Event News

 
Latest News

Ultrathin device harvests electricity from human motion

24.07.2017 | Power and Electrical Engineering

Scientists announce the quest for high-index materials

24.07.2017 | Materials Sciences

ADIR Project: Lasers Recover Valuable Materials

24.07.2017 | Materials Sciences

VideoLinks
B2B-VideoLinks
More VideoLinks >>>